Apex Medical Corporation, a $75 million company and a major player in the respiratory therapy and pressure area care sectors, has made its debut into Indian market with the launch of its three main product verticals - respiratory, support surface and autoclaves primarily as their core offering in India.

The company has a long term plan for the Indian market and will proceed in phases in a strategic manner, Apex said.

In the next few years, with an aggressive growth plan, Apex in India expects to grow at a CAGR of 30 percent.

Founded in the year 1990, Apex Medical is headquartered in Taiwan, the company caters to Europe, United States, Asia and other international markets through an established network of international subsidiaries and partners.

Apex invests 5 percent of its annual revenue into R&D.

Speaking at the occasion, Mr Daniel Lee, CEO, Apex Medical, said, "...We look forward to be part of this continuously growing healthcare industry in India. As the Indian market is growing at 7-8 percent with healthcare market growing at 12-15 percent, we expect Apex in India to grow at least by 5 times in the next five years...."

Mr Puneet Sahai is the current president of Apex Medical India.